Evidence map›Paper›PMID 35710652›Full record

ArticleScientific data2022

CF-Seq, an accessible web application for rapid re-analysis of cystic fibrosis pathogen RNA sequencing studies.

Samuel L Neff, Thomas H Hampton, Charles Puerner, Liviu Cengher, Georgia Doing, Alexandra J Lee, Katja Koeppen, Ambrose L Cheung, Deborah A Hogan, Robert A Cramer and 1 more

Abstract readDataset
In one paragraph

Article in Scientific data, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Bridging bench and bedside: translational omics ofEuropean respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  2. Article
  3. Article
  4. Microbiology spectrum · 2024
    Article
  5. Article
  6. Analysis ofbioRxiv : the preprint server for biology · 2023
    Article
  7. Article
  8. Article
  9. Using genome-wide expression compendia to study microorganisms.Computational and structural biotechnology journal · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Samuel L NeffGeisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Thomas H HamptonGeisel School of Medicine, Dartmouth College, Hanover, NH, USA.ORCID 0000-0003-0543-402X
Charles PuernerGeisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Liviu CengherGeisel School of Medicine, Dartmouth College, Hanover, NH, USA.ORCID 0000-0003-0130-2695
Georgia DoingGeisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Alexandra J LeeUniversity of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-0208-3730
Katja KoeppenGeisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Ambrose L CheungGeisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Deborah A HoganGeisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Robert A CramerGeisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Bruce A StantonGeisel School of Medicine, Dartmouth College, Hanover, NH, USA. Bruce.A.Stanton@dartmouth.edu.

Funding

Translational Research CoreP30DK117469 · NIDDK · DARTMOUTH COLLEGE · PI DEAN R MADDEN · 2018 to 2026
$13.9M
Environmental Oxygen Transitions and Aspergillosis Disease ProgressionR01AI146121 · NIAID · DARTMOUTH COLLEGE · PI CRAMER, ROBERT ANDREW · 2019 to 2023
$2.6M
Retrieval, Reprocessing, Normalization and Sharing of Gene Expression and Lung Microbiome Data Sets to Facilitate AI/ML Analysis Studies of Bacterial Lung InfectionsR01HL151385 · NHLBI · DARTMOUTH COLLEGE · PI STANTON, BRUCE A. · 2021 to 2024
$2.4M
Dartmouth Cystic Fibrosis Training ProgramT32HL134598 · NHLBI · DARTMOUTH COLLEGE · PI George A. O'Toole · 2017 to 2026
$1.7M
NHLBI NIH HHS R01 HL151385NHLBI NIH HHS T32 HL134598NIAID NIH HHS R01 AI146121NIDDK NIH HHS P30 DK117469
6 · The paper itself

Abstract

Researchers studying cystic fibrosis (CF) pathogens have produced numerous RNA-seq datasets which are available in the gene expression omnibus (GEO). Although these studies are publicly available, substantial computational expertise and manual effort are required to compare similar studies, visualize gene expression patterns within studies, and use published data to generate new experimental hypotheses. Furthermore, it is difficult to filter available studies by domain-relevant attributes such as strain, treatment, or media, or for a researcher to assess how a specific gene responds to various experimental conditions across studies. To reduce these barriers to data re-analysis, we have developed an R Shiny application called CF-Seq, which works with a compendium of 128 studies and 1,322 individual samples from 13 clinically relevant CF pathogens. The application allows users to filter studies by experimental factors and to view complex differential gene expression analyses at the click of a button. Here we present a series of use cases that demonstrate the application is a useful and efficient tool for new hypothesis generation. (CF-Seq: http://scangeo.dartmouth.edu/CFSeq/ ).

Indexed as

Cystic FibrosisSequence Analysis, RNAData AnalysisHumansRNA-SeqSoftware

Identifiers

PMID35710652
PMCPMC9203545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.